Sugi Predict

Sugi Predict / Compounds / SCHEMBL2636731

SCHEMBL2636731

SCHEMBL2636731

O=C(O)c1ccc(-c2ccc(F)cc2)cn1

nearest known ligand 0.57

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ P4HTM Q9NXG6 9/20 0.57
▸ BCL2L1 Q07817 1/20 0.53
▸ BAD Q92934 1/20 0.53
▸ P4HA1 P13674 1/20 0.52
▸ MIF P14174 1/20 0.52
▸ KDM4E B2RXH2 4/20 0.50
▸ ALDH1A1 P00352 1/20 0.50
▸ MAP4K4 O95819 2/20 0.49
▸ EGLN1 Q9GZT9 1/20 0.44
▸ HIF1A Q16665 1/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ ASPH Q12797 1/20 0.43
▸ KDM8 Q8N371 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29928830 1.00 P4HTM (0.57) P4HTMBCL2L1BADP4HA1MIF
SCHEMBL13731115 0.88 P4HTM (0.64) P4HTMP4HA1MIFKDM4EALDH1A1
SCHEMBL16595457 0.85 BCL2L1 (0.46) P4HTMBCL2L1BADMAP4K4EGLN1
SCHEMBL29929320 0.84 HIF1A (0.55) P4HTMP4HA1MIFKDM4EALDH1A1
SCHEMBL71034 0.84 HIF1A (0.55) P4HTMP4HA1MIFKDM4EALDH1A1
SCHEMBL110129 0.84 P4HTM (0.59) P4HTMP4HA1MIFKDM4EALDH1A1
SCHEMBL30449388 0.84 P4HTM (0.59) P4HTMP4HA1MIFKDM4EALDH1A1
SCHEMBL14815618 0.83 GRIN1 (0.45) P4HTMBCL2L1BADALDH1A1MAP4K4
SCHEMBL27961477 0.83 KMT2A (0.51) BCL2L1BADMAP4K4MAPK1
SCHEMBL11044314 0.82 P4HTM (0.53) P4HTMBCL2L1P4HA1MIFKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008001160-A1 MELANIN CONCENTRATING HORMONE ANTAGONISTS THE PROCTER & GAMBLE COMPANY (US) 2008-01-03 — — WO claimed
US-20060247239-A1 Melanin concentrating hormone antagonists HU XIUFENG E 2006-11-02 — — US claimed
EP-3710428-B1 MODULATORS OF THE INTEGRATED STRESS PATHWAY CALICO LIFE SCIENCES LLC (US) 2026-03-25 — — EP disclosed
US-20250346585-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2025-11-13 — — US disclosed
WO-2025091127-A1 HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF UNIVERSITE DE MONTREAL (CA) 2025-05-08 — — WO disclosed
US-20240307382-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ABBVIE INC. 2024-09-19 — — US disclosed
CN-112204009-B Modulators of integrated stress pathways 卡里科生命科学有限责任公司 2024-05-07 — — CN disclosed
CN-112204009-A Modulators of integrated stress pathways 卡里科生命科学有限责任公司 2021-01-08 — — CN disclosed
US-20200345727-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ABBVIE INC. 2020-11-05 — — US disclosed
EP-3710428-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY Calico Life Sciences LLC (US) 2020-09-23 — — EP disclosed
CN-109180671-A Imino group thiadiazine dioxide derivative and application thereof 广东东阳光药业有限公司 2019-01-11 — — CN disclosed
EP-1828177-B1 NOVEL MCH RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2008-08-13 — — EP disclosed
WO-2008001160-A1 MELANIN CONCENTRATING HORMONE ANTAGONISTS THE PROCTER & GAMBLE COMPANY (US) 2008-01-03 — — WO disclosed
US-20070207991-A1 Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-09-06 — — US disclosed
US-7223788-B2 therapy for eating disorders, anorexigenic agents, antidiabetic agents, reducing weight in mammals, circadian rhythm disease, psychological disorders SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-05-29 — — US disclosed
US-20060247239-A1 Melanin concentrating hormone antagonists HU XIUFENG E 2006-11-02 — — US disclosed
CN-1835950-A Imidazopyridine derivatives BANYU PHARMA CO LTD (JP) 2006-09-20 — — CN disclosed
EP-1657242-A1 IMIDAZOPYRIDINE DERIVATIVES Banyu Pharmaceutical Co., Ltd. (JP) 2006-05-17 — — EP disclosed
CN-1774418-A Substituted N-arylheterocycles, method for production and use thereof as medicaments AVENTIS PHARMA GMBH (DE) 2006-05-17 — — CN disclosed
US-20040220191-A1 Substituted N-aryl heterocycles, process for their preparation and their use as medicaments AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-11-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220191-A1 Substituted N-aryl heterocycles, process for their preparation and their use as medicaments CYP11B2, CYP11B1, CYP1A1 P4HTM 368/4885BCL2L1 3191/4885BAD 1708/4885
US-20060247239-A1 Melanin concentrating hormone antagonists MCHR1, MCHR2, MC1R P4HTM 642/4885BCL2L1 4791/4885BAD 4023/4885
US-20250346585-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS C5, C1S, C9 P4HTM 889/4885BCL2L1 4374/4885BAD 3838/4885
US-20240307382-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ATF4, ATF1, DDIT3 P4HTM 2470/4885BCL2L1 2293/4885BAD 2738/4885
US-20070207991-A1 Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments CYP11B2, CYP11B1, NQO1 P4HTM 357/4885BCL2L1 3319/4885BAD 1515/4885
US-20200345727-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ATF4, ATF1, DDIT3 P4HTM 2470/4885BCL2L1 2293/4885BAD 2738/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.